CoChat

Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge

Open access
Parrott, Jennifer M., Redus, Laney, O’Connor, Jason C. · 2016 · Journal of Neuroinflammation

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Inflammation increases the risk of developing depression-related symptoms, and tryptophan metabolism is an important mediator of these behavior changes. Peripheral immune activation results in central up-regulation of pro-inflammatory cytokine expression, microglia activation, and the production of neurotoxic kynurenine metabolites. The neuroinflammatory and kynurenine metabolic response to peripheral immune activation has been largely characterized at the whole brain level. It is unknown if this metabolic response exhibits regional specificity even though the unique indoleamine 2,3-dioxygenase (IDO)-dependent depressive-like behaviors are known to be controlled by discrete brain regions. Therefore, regional characterization of neuroinflammation and kynurenine metabolism might allow for better understanding of the potential mechanisms that mediate inflammation-associated behavior changes. METHODS: Following peripheral immune challenge with lipopolysaccharide (LPS), brain tissue from behaviorally relevant regions was analyzed for changes in mRNA of neuroinflammatory targets and kynurenine pathway enzymes. The metabolic balance of the kynurenine pathway was also determined in the peripheral circulation and these brain regions. RESULTS: Peripheral LPS treatment resulted in region-independent up-regulation of brain expression of pro-inflammatory cytokines and glial cellular markers indicative of a neuroinflammatory response. The expression of kynurenine pathway enzymes was also largely region-independent. While the kynurenine/tryptophan ratio was elevated significantly in both the plasma and in each brain regions evaluated, the balance of kynurenine metabolism was skewed toward production of neurotoxic metabolites in the hippocampus. CONCLUSIONS: The upstream neuroinflammatory processes, such as pro-inflammatory cytokine production, glial cell activation, and kynurenine production, may be similar throughout the brain. However, it appears that the balance of downstream kynurenine metabolism is a tightly regulated brain region-dependent process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-016-0590-y

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Kynurenine pathway of tryptophan metabolism. Tryptophan is metabolized to kynurenine by indoleamine 2,3-dioxygenase (IDO), IDO-like enzyme, IDO2, and tryptophan 2,3-dioxygenase (TDO). Tryptophan can also be metabolized by tryptophan hydroxylase (TrpH) and l-aromatic amino acid decarboxylase (L -AADC) to serotonin (5-HT) which is further broken down by monoamine oxidase (MAO) to 5-hydroxyindoleacetic acid (5-HIAA). Kynurenine can be metabolized to kynurenic acid (KA) by one of four isoforms of kynurenine aminotransferase (KAT), of which KATI and KATII are most relevant to mammals. The production of KA by KATs mainly occurs in astrocytes, cells which predominantly express glial fibrillary acidic protein (GFAP). Alternately, kynurenine can be metabolized to 3-hydroxykynurenine (3-HK) by kynurenine 3-monooxygenase (KMO). 3-HK is metabolized to 3-hydroxyanthranilic acid (3-HAA) by kynureninase (KYNU) and 3-HAA to quinolinic acid (QA) by 3-hydroxyanthranilic acid dioxygenase (HAAO). This branch of the kynurenine pathway is compartmentalized in microglia, indicated by ionized calcium-binding adapter molecule 1 (Iba1) and CD11b expression. The elevation in expression of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), and interleukin-6 (IL-6), during inflammatory conditions activates glial cells. Further, IDO expression is up-regulated and flux through the neurotoxic kynurenine metabolic branch increases. Underlined targets were assessed by real-time RT-PCR to determine changes in mRNA
Fig. 1 Kynurenine pathway of tryptophan metabolism. Tryptophan is metabolized to kynurenine by indoleamine 2,3-dioxygenase (IDO), IDO-like enzyme, IDO2, and tryptophan 2,3-dioxygenase (TDO). Tryptophan can also be metabolized by tryptophan hydroxylase (TrpH) and l-aromatic amino acid decarboxylase (L -AADC) to serotonin (5-HT) which is further broken down by monoamine oxidase (MAO) to 5-hydroxyindoleacetic acid (5-HIAA). Kynurenine can be metabolized to kynurenic acid (KA) by one of four isoforms of kynurenine aminotransferase (KAT), of which KATI and KATII are most relevant to mammals. The production of KA by KATs mainly occurs in astrocytes, cells which predominantly express glial fibrillary acidic protein (GFAP). Alternately, kynurenine can be metabolized to 3-hydroxykynurenine (3-HK) by kynurenine 3-monooxygenase (KMO). 3-HK is metabolized to 3-hydroxyanthranilic acid (3-HAA) by kynureninase (KYNU) and 3-HAA to quinolinic acid (QA) by 3-hydroxyanthranilic acid dioxygenase (HAAO). This branch of the kynurenine pathway is compartmentalized in microglia, indicated by ionized calcium-binding adapter molecule 1 (Iba1) and CD11b expression. The elevation in expression of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), and interleukin-6 (IL-6), during inflammatory conditions activates glial cells. Further, IDO expression is up-regulated and flux through the neurotoxic kynurenine metabolic branch increases. Underlined targets were assessed by real-time RT-PCR to determine changes in mRNACC BY · PubMed Central
Fig. 2 Central pro-inflammatory cytokines are elevated following peripheral LPS injections. mRNA fold changes (ΔmRNA) of interleukin-1β (IL-1β, left panel), tumor necrosis factor α (TNFα, middle panel), and interleukin-6 (IL-6, right panel) were measured at 6 and 24 h post LPS treatment in the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. * = post hoc comparison to saline treatment group. *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
Fig. 2 Central pro-inflammatory cytokines are elevated following peripheral LPS injections. mRNA fold changes (ΔmRNA) of interleukin-1β (IL-1β, left panel), tumor necrosis factor α (TNFα, middle panel), and interleukin-6 (IL-6, right panel) were measured at 6 and 24 h post LPS treatment in the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. * = post hoc comparison to saline treatment group. *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001CC BY · PubMed Central
Fig. 3 Peripheral inflammation up-regulates central expression of glial cell markers. mRNA fold changes (ΔmRNA) of CD11b (left panel), ionized calcium-binding adapter molecule 1 (Iba1, middle panel), and glial fibrillary acid protein (GFAP, right panel) were measured at 6 and 24 h post LPS treatment in the a hippocampus, b amygdala, and c striatum. Data represent sample means ± SEM, n = 9–11 samples/group. * = overall significance or post hoc comparison to saline treatment group. *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
Fig. 3 Peripheral inflammation up-regulates central expression of glial cell markers. mRNA fold changes (ΔmRNA) of CD11b (left panel), ionized calcium-binding adapter molecule 1 (Iba1, middle panel), and glial fibrillary acid protein (GFAP, right panel) were measured at 6 and 24 h post LPS treatment in the a hippocampus, b amygdala, and c striatum. Data represent sample means ± SEM, n = 9–11 samples/group. * = overall significance or post hoc comparison to saline treatment group. *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001CC BY · PubMed Central
Fig. 4 Peripheral LPS specifically increases expression of kynurenine producing enzyme, indoleamine 2,3-dioxygenase (IDO). mRNA fold changes (ΔmRNA) of IDO were assessed at 6 and 24 h following LPS injections in the (a) hippocampus, (b) amygdala, and (c) striatum. mRNA expression of IDO2 (left panel) and tryptophan 2,3-dioygenase (TDO, right panel) were also measured at 6 and 24 h post LPS in the (d) hippocampus, (e) amygdala, and (f) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. #,* = overall significance or post hoc comparison to saline treatment group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
Fig. 4 Peripheral LPS specifically increases expression of kynurenine producing enzyme, indoleamine 2,3-dioxygenase (IDO). mRNA fold changes (ΔmRNA) of IDO were assessed at 6 and 24 h following LPS injections in the (a) hippocampus, (b) amygdala, and (c) striatum. mRNA expression of IDO2 (left panel) and tryptophan 2,3-dioygenase (TDO, right panel) were also measured at 6 and 24 h post LPS in the (d) hippocampus, (e) amygdala, and (f) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. #,* = overall significance or post hoc comparison to saline treatment group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001CC BY · PubMed Central
Fig. 5 Kynurenine aminotransferases expression following peripheral LPS treatment. mRNA fold changes (ΔmRNA) of kynurenine aminotransferase I (KAT I, left panel) and kynurenine aminotransferase II (KAT II, right panel) were measured at 6 and 24 h post LPS in the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. #,* = overall significance or post hoc comparison to saline treatment group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
Fig. 5 Kynurenine aminotransferases expression following peripheral LPS treatment. mRNA fold changes (ΔmRNA) of kynurenine aminotransferase I (KAT I, left panel) and kynurenine aminotransferase II (KAT II, right panel) were measured at 6 and 24 h post LPS in the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. #,* = overall significance or post hoc comparison to saline treatment group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001CC BY · PubMed Central
Fig. 6 Peripheral inflammation alters expression of downstream kynurenine pathway enzymes. mRNA fold changes (ΔmRNA) of kynurenine 3-monooxygenase (KMO, left panel), kynureninase (KYNU, middle panel), and 3-hydroxyanthranilic acid dioxygenase (HAAO, right panel) were measured at 6 and 24 h following LPS injections in the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample means ± SEM, n = 9–11 samples/group. #,* = post hoc comparison to saline treatment group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
Fig. 6 Peripheral inflammation alters expression of downstream kynurenine pathway enzymes. mRNA fold changes (ΔmRNA) of kynurenine 3-monooxygenase (KMO, left panel), kynureninase (KYNU, middle panel), and 3-hydroxyanthranilic acid dioxygenase (HAAO, right panel) were measured at 6 and 24 h following LPS injections in the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample means ± SEM, n = 9–11 samples/group. #,* = post hoc comparison to saline treatment group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001CC BY · PubMed Central
Fig. 7 Kynurenine/tryptophan ratio and hippocampal neurotoxic kynurenine metabolite ratio are up-regulated in response to peripheral LPS. The kynurenine/tryptophan ratio was measured at 24 h following LPS injections in the (a) dorsal hippocampus, (b) ventral hippocampus, (c) central amygdala, and (d) nucleus accumbens. Metabolite ratios of 3-hydroxykynurenine/kynurenic acid (3-HK/KA, neurotoxic ratio, left panel) and 5-hydroxyindoleacetic acid/serotonin (5-HIAA/5-HT, serotonin turnover, right panel) were measured 24 h post LPS in the (e) dorsal hippocampus, (f) ventral hippocampus, (g) central amygdala, and (h) nucleus accumbens. Data represent sample means ± SEM, n = 7–12 samples/group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
Fig. 7 Kynurenine/tryptophan ratio and hippocampal neurotoxic kynurenine metabolite ratio are up-regulated in response to peripheral LPS. The kynurenine/tryptophan ratio was measured at 24 h following LPS injections in the (a) dorsal hippocampus, (b) ventral hippocampus, (c) central amygdala, and (d) nucleus accumbens. Metabolite ratios of 3-hydroxykynurenine/kynurenic acid (3-HK/KA, neurotoxic ratio, left panel) and 5-hydroxyindoleacetic acid/serotonin (5-HIAA/5-HT, serotonin turnover, right panel) were measured 24 h post LPS in the (e) dorsal hippocampus, (f) ventral hippocampus, (g) central amygdala, and (h) nucleus accumbens. Data represent sample means ± SEM, n = 7–12 samples/group. # p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Research works printed but not linked: 1

  1. Franklin KBJ, Paxinos G. The mouse brain in sterotaxic coordinates. 3rd ed. New York, NY: Academic Press; 2007.

Cited by

See all 112

Metadata

Authors
Parrott, J. M., Redus, L., & O’Connor, J. C.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
Corresponding author
O’Connor, Jason C.
Venue
Journal of Neuroinflammation
Published
2016-05-27
Volume
13
Issue
1
Pages
124-124
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2401414122
Cited by
112
References
73
Citations by year
2026: 10 · 2025: 10 · 2024: 18 · 2023: 7 · 2022: 8 · 2021: 17 · 2020: 16 · 2019: 12 · 2018: 5 · 2017: 8 · 2016: 1
FWCI
2.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute of Mental Health (P30MH089868, 1F31MH102070-01A1)
  • National Center for Advancing Translational Sciences (UL1TR001120)
  • Norman Hackerman Advanced Research Program (003659-0010-2012)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
kynurenine metabolism, hippocampus, lipopolysaccharide, neuroinflammation, tryptophan metabolism, indoleamine 2,3-dioxygenase, inflammatory cytokines, microglial activation, depression, regional specificity, peripheral immune activation
MeSH terms
Animals, Brain, Calcium-Binding Proteins, Chromatography, Liquid, Disease Models, Animal, Glial Fibrillary Acidic Protein, Kynurenine, Lipopolysaccharides, Male, Mice, Inbred C57BL, Microfilament Proteins, RNA, Messenger, Mass Spectrometry, Time Factors, Signal Transduction, Cytokines, Neurogenic Inflammation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge. https://app.cochat.ai/papers/10.1186/s12974-016-0590-y
The paper
Parrott, J. M., Redus, L., & O’Connor, J. C. (2016). Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0590-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.